| (EXELIXIS) XL184-312 / COSMIC-312 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Meyers, Dr Brandon | Open to recruitment | NCT03755791 |
| (Merck) MK-3475-966 | Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract Carcinoma | Kazemi, Dr Ghazaleh | Open to recruitment | NCT04003636 |
| (AstraZeneca) D910DC00001 / EMERALD-2 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation. | Meyers, Dr Brandon | Recruitment on hold - COVID-19 | NCT03847428 |
| (AstraZeneca) D933GC00001 / EMERALD-1 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma | Zbuk, Dr Kevin | Recruitment on hold - COVID-19 | NCT03778957 |
| (CCTG) CO.21 / CHALLENGE | A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) | Goffin, Dr John | Recruitment on hold - COVID-19 | NCT00819208 |
| (UHN) OZM-067 / LuNET | A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor positive Neuroendocrine Tumors | Juergens, Dr Rosalyn | Recruitment on hold - COVID-19 | NCT02743741 |
| RTOG 1112 | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Swaminath, Dr Anand | Recruitment on hold - COVID-19 | NCT01730937 |
Find a Trial
Contact Us